The U.S. continues to notch record Covid-19 infections, with the national seven-day average of daily new cases hitting 170,855 on Sunday, according to a CNBC analysis of Johns Hopkins University data. It's possible the numbers will get a little more opaque heading into the holiday weekend. Local health outposts typically pause reporting for national holidays, which could lead to slight backlogs.
Here are some of the biggest developments Monday:
The following data was compiled by Johns Hopkins University:
- Global cases: More than 58.79 million
- Global deaths: At least 1.39 million
- U.S. cases: More than 12.25 million
- U.S. deaths: At least 256,803
For grocery workers, the latest wave of Covid-19 brings feeling of deja vu
Grocery workers said as Covid-19 cases rise across the country, they have heightened anxiety and a terrible feeling of deja vu.
Hand sanitizer and masks are in short supply. Some shoppers walk through stores without wearing a mask. And pandemic-related policies, from extra store cleanings to limits on the number of customers, have largely faded away, according to members of the United Food and Commercial Workers International Union who spoke on a Monday conference call.
This time, however, the pandemic and holiday rush have collided. Shoppers are heading to stores for holiday items, such as turkeys and baking supplies, along with stocking up again on toilet paper. And extra hourly pay meant to show appreciation or compensate for additional health risks has ended.
"If you want to know one reason why this pandemic is getting worse, it's very simple: We haven't learned. We haven't changed," said Janet Wainwright, a five-year employee of Kroger who works in Virginia.
At least 350 of the grocery union's members have died since the start of the pandemic, including 109 grocery workers. More than 48,000 members have gotten sick or been exposed to Covid-19, according to UFCW. That total does not include workers who have gotten sick or died at nonunionized retailers like Walmart and Amazon.
Doctors say vaccine shots won't be 'a walk in the park'
Doctors urged public health officials and drugmakers to be transparent about the side effects people may experience after getting their first Covid-19 vaccine shots from either Moderna or Pfizer.
During a meeting with the CDC's Advisory Committee on Immunization Practices, Dr. Sandra Fryhofer of the American Medical Association said U.S. officials "really need to make patients aware that this is not going to be a walk in the park."
"They are going to know they had a vaccine," she said during the meeting. "They are probably not going to feel wonderful. But they've got to come back for that second dose."
The committee meeting comes three days after Pfizer and its partner BioNTech applied for an emergency use authorization from the FDA for their vaccine. Moderna and Pfizer have acknowledged that their vaccines could induce side effects that are similar to symptoms associated with mild Covid-19, such as muscle pain, chills and headache.
–Berkeley Lovelace Jr.
Covid precautions still needed, but vaccine data offers optimism for 2021, doctor says
Dr. Jeremy Faust, an emergency room doctor at Brigham and Women's Hospital in Boston, told CNBC that the recent spate of optimistic Covid-19 vaccine data offers hope for 2021. But Faust also said it underscores the need for public-health precautions in the next few months.
"We have to acknowledge that there actually is a saving grace possibly coming here and it's not just flattening the curve now. It's saving lives," Faust said on "Power Lunch."
In the initial outbreak this spring, when vaccines seemed potentially a year away, people were told the health restrictions were critical to prevent hospitals from becoming overrun. Now, Pfizer has applied for emergency use authorization with the FDA, and Moderna and AstraZeneca appear to have promising vaccines as well.
"I never imagined we would have three products in three weeks with these kinds of data," Faust said, adding that there could still be challenges with rolling out the vaccines to Americans. Nonetheless, the promising developments mean the worst of the pandemic may be in sight, he said.
"We can't just say, 'Oh, it's just a matter of time before I get it and we'll see how it goes,'" Faust said. "No, now we know that sometime in 2021, there's going to be a vaccine likely that's safe and effective in your arm. Let's all get there together."
— Kevin Stankiewicz
New York to reopen 100-bed field hospital on Staten Island, Cuomo says
New York Gov. Andrew Cuomo said the state will reopen a field hospital on Staten Island following an influx of Covid-19 patients over the last three weeks.
The 100-bed facility was one of many New York opened in the spring as it fought back a wave of coronavirus infections that overwhelmed its hospital system and killed roughly 800 people every day. However, those emergency facilities largely went unused, Cuomo said.
"This was a planned emergency facility in the spring. We didn't use it; now we need it," Cuomo said during a press briefing. There were 91 people hospitalized with Covid-19 on Staten Island as of Sunday, a near threefold increase from three weeks ago, he said.
California Gov. Newsom in quarantine following potential Covid exposure
California Gov. Gavin Newsom said in a tweet that he and his family will quarantine for the next two weeks following a potential coronavirus exposure.
Newsom said he and first lady Jennifer Siebel Newsom learned on Friday evening that their three of their children had been exposed to a California Highway Patrol officer who tested positive for Covid-19. The Democratic governor was not directly exposed to the officer, he said, and so far the family has tested negative for the virus.
— Noah Higgins-Dunn
Hospital workers at risk due to 'unprecedented' Covid spread, CEO says
Dr. Penny Wheeler, the chief executive of Minneapolis-based Allina Health, told CNBC that the sharp uptick in coronavirus cases puts hospital workers at higher risk of becoming infected. While hospitals were able to improve supply of masks and ventilators since the spring outbreak, it's harder to have more nurses and doctors, she said.
"You cannot manufacture a talented and compassionate caregiver," Wheeler said in a "Squawk on the Street" interview. "And that's where we're having trouble with now, especially with so many of them being affected or their family members being affected by community spread in our organization and in the community."
As the Midwest, in particular, sees an "unprecedented" surge in cases, Wheeler said the general public should adhere to public health mitigations more stringently. "The need for masking, physical distancing and washing of hands, all those things — I know people are fatigued but so are the health-care workers, and you can keep our health-care workers healthier and able to care for you if you do those things," she said.
Amazon asking holiday shoppers to use pick up hubs amid surge of online orders
Amazon is pushing shoppers to get their packages delivered to some of its brick-and-mortar retail locations and neighborhood "hubs," as it faces a pandemic-fueled surge of online orders, coupled with the holiday season.
The company now accepts deliveries at its physical bookstores, called Amazon Books, or Amazon 4-star stores. Amazon also highlighted its network of contactless pickup points, referred to as Amazon Hubs, as an "alternative delivery location."
By encouraging shoppers to have their orders sent to Hubs and brick-and-mortar stores, Amazon can cut down on the number of last-mile delivery trips that are necessary.
Amazon will likely need all the help it can get when it comes to deliveries this holiday season. For months, large shippers such as FedEx and UPS have been warning of a potential capacity shortfall, as the spike of e-commerce activity and holiday peak leaves them struggling to keep up.
Regeneron will provide 300,000 doses of treatment for U.S. by early January, CEO says
Regeneron CEO Dr. Leonard Schleifer told CNBC that the company will provide the U.S. 300,000 doses of its newly authorized coronavirus treatment by early January, and it has 80,000 doses ready to deploy immediately.
The Food and Drug Administration on Saturday granted an emergency use authorization for the company's antibody treatment, called REGN-COV2, which was given to President Donald Trump when he contracted the coronavirus in October.
After January, Regeneron will have the ability to supply 100,000 doses every month, Schleifer said. The company is also conducting experiments to determine whether the dosage can be cut in half, which would eventually double the number of available doses to 200,000 every month if proven effective, he said.
"We hope to have millions of doses available," Schleifer told CNBC's "Squawk Box."
United launches preflight Covid-19 testing for Latin America, Caribbean flights
United Airlines customers traveling to Latin American and Caribbean destinations from its George Bush Intercontinental Airport hub in Houston could take a preflight Covid test starting next month to avoid quarantines or travel bans. The destinations include Belize City; Guatemala City; Lima, Peru; Nassau, Bahamas; San Salvador; and Panama City.
The self-collected tests will cost travelers $119 and be processed by Advanced Diagnostic Laboratory in San Antonio. United said it will reach out to customers with instructions two weeks before their flights.
United and other airlines have been scrambling to advance testing regimes to ease travel in the pandemic. Last week, United began a trial of free preflight Covid tests for some London-bound passengers and last month started a preflight testing program for travelers flying to Hawaii from San Francisco.
Merck buys OncoImmune to boost supply of promising Covid drug
Pharmaceutical giant Merck said it plans to acquire OncoImmune, gaining rights to an under-the-radar drug that has shown promising results in patients hospitalized with Covid-19, CNBC's Meg Tirrell reports.
The drug, CD24Fc, was found in a late-stage clinical study to reduce the risk of respiratory failure or death by more than 50% in patients requiring oxygen, Merck said Monday. But OncoImmune was too small to reach scale, Merck's research chief, Dr. Roger Perlmutter, told CNBC.
"We realized that this small little company was in no position to make CD24Fc to try and treat all of the people who could potentially benefit from this drug," Perlmutter said. "We decided that the only way, seriously, that this could be brought to people who need it is for us to lean in with our capabilities."
Retailers try to limit holiday crowds by trading doorbusters for weeks of deals
Don't call it a "doorbuster." Many retailers are putting some of their deepest holiday discounts and popular gift items online this year.
At Best Buy